HTR1A, HTR1B, HTR2A, and HTR2B were commonly targeted in preclinical studies for the anxiety treatment (Graeff et al., 1996; Clinard et al., 2015; Spiacci et al., 2016; Colangeli et al., 2019) as well as the anxiolytic-like studies of SZJ (Wang et al., 2010; Liu et al., 2015). The gene discussed is HTR2B; the disease is Anxiety.